Care your patients can count on
CrinetiCARE offers personalized support to help your eligible patients throughout their treatment journey with PALSONIFY™ (paltusotine).
Patricia,
living with acromegaly
About CrinetiCARE
CrinetiCARE provides access and reimbursement support to help patients start and stay on therapy with PALSONIFY. From helping your patients navigate insurance coverage to connecting with nurse educators, CrinetiCARE is here to help support access.
Key support services
- Benefits investigation
- Appeals
- Financial support
- Nurse educators
Financial support
CrinetiCARE provides financial assistance programs to help your eligible patients access treatment with PALSONIFY. Our dedicated team works directly with patients and their insurance providers to minimize out-of-pocket costs.
Quick start supply
Patients who experience a delay in their insurance coverage determination can begin therapy while the CrinetiCARE team works on securing insurance coverage.
Copay assistance program
Eligible commercially insured patients who are not insured by any federal or government-funded program may pay as little as $0 for PALSONIFY.*
Patient assistance program
Eligible uninsured or underinsured patients may be able to receive PALSONIFY at no cost.†
When your patients enroll in CrinetiCARE, we’ll help determine their eligibility and guide them through accessing the financial support they may need.
Megan,
living with acromegaly
Additional support organizations
*Terms and conditions apply. Patients are eligible for copay assistance if enrolled in private commercial health insurance and are not covered by state or federal healthcare programs, and who meet the eligibility criteria. Patients will be enrolled for 12 months. There are no income requirements to participate in the program.
†Criteria include patients who are uninsured or have insurance that excludes coverage for PALSONIFY (including patients on Medicare or Medicaid), residents of the United States or Puerto Rico, and patients who meet the financial eligibility requirements. Terms and conditions apply.
Acromegaly control across a range of patients1
PALSONIFY provided rapid and reliable IGF-1 control along with consistent symptom control, all with a low discontinuation rate. IGF-1 reduction was observed in 2 to 4 weeks in most patients with uncontrolled acromegaly while IGF-1 control was maintained in most patients switching from iSRLs. Consistent symptom control was observed with an overall reduction in symptom severity vs a worsening of symptoms with placebo. Additionally, sustained biochemical control was maintained for more than a year in ongoing uncontrolled open-label studies.1-4
PATHFNDR-1 CLINICAL TRIAL
PALSONIFY seamlessly maintained IGF-1 control in patients who switched from SRL injections (octreotide or lanreotide).1
PATHFNDR-2 CLINICAL TRIAL
PALSONIFY proved effective in patients who were biochemically uncontrolled, including treatment naïve.1
IGF-1=insulin-like growth factor 1; iSRLs=injected somatostatin receptor ligands; SRL=somatostatin receptor ligand.
Nurse educators*
education, help answer common questions about therapy, and provide consistent, ongoing support throughout your patient’s journey with PALSONIFY.
Your patients can reach a nurse at
*Nurse educators do not provide medical advice.
Specialty
pharmacy
Resources
Access resources and downloadable forms to support your patients throughout their PALSONIFY treatment journey.
PALSONIFY letter of medical necessity
A template to document medical necessity for PALSONIFY, including required patient information for coverage requests.
PALSONIFY letter of appeals
A template letter to support appeals of insurance coverage denials for PALSONIFY treatment.
Enrollment form
Patient enrollment and eligibility verification form for CrinetiCARE program registration.
Access and reimbursement guide
Guide for insurance coverage, reimbursement processes, and financial assistance options.
HCP hub brochure
Overview of HCP services and support available through the CrinetiCARE program.
PALSONIFY brochure
An informational brochure with key facts about PALSONIFY, including how it works, benefits, and Important Safety Information.
Medicare coverage guide
A comprehensive guide to help your patients understand their Medicare coverage options for PALSONIFY treatment.
Patient Information
Provides important information about how to take medication safely, including possible side effects.
Support with CoverMyMeds®
INDICATION:
PALSONIFY is a somatostatin receptor agonist indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS:
- Cholelithiasis and Its Complications: Cholelithiasis, including related complications such as acute cholecystitis and pancreatitis, have been reported. Monitor patients periodically. Discontinue PALSONIFY if complications of cholelithiasis occur and treat appropriately.
- Hyperglycemia and Hypoglycemia: Hyperglycemia, diabetes mellitus, or hypoglycemia, may occur. Monitor blood glucose levels when PALSONIFY treatment is initiated or when dosage is altered. Adjust antidiabetic treatment accordingly.
- Cardiovascular Abnormalities: Cardiac conduction abnormalities and other ECG changes such as PR interval prolongation, bradycardia, sinus arrest, and atrioventricular block may occur in patients with acromegaly and were reported in PALSONIFY clinical trials. Dosage adjustments of concomitant drugs that have bradycardic effects may be necessary.
- Thyroid Function Abnormalities: Somatostatin analogs may suppress the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. Periodic assessment of thyroid function is recommended.
- Steatorrhea and Malabsorption of Dietary Fats: Somatostatin analog treatment may result in malabsorption of dietary fats and subsequent symptoms of steatorrhea, loose stools, abdominal bloating, and weight loss. If new or worsening symptoms are reported with PALSONIFY, evaluate patients for potential pancreatic exocrine insufficiency and manage accordingly.
- Vitamin B12 Deficiency: Vitamin B12 deficiency may occur. Monitor vitamin B12 levels, if clinically indicated.
ADVERSE REACTIONS:
Most common adverse reactions (>5%) are diarrhea, abdominal pain, nausea, decreased appetite, sinus bradycardia, hyperglycemia, palpitations, and gastroenteritis.
DRUG INTERACTIONS:
- Strong or Moderate CYP3A4 Inducers: may decrease PALSONIFY exposure. May require an increased dosage of PALSONIFY.
- Proton Pump Inhibitors: may decrease PALSONIFY exposure. May require an increased dosage of PALSONIFY. Avoid concomitant use of proton pump inhibitors in patients who are already on PALSONIFY 60 mg.
- Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment when used with PALSONIFY; follow therapeutic monitoring recommendations.
Please report adverse events to Crinetics Pharmaceuticals at 1‑833‑CRN‑INFO (1‑833‑276‑4636) or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.
Please see Full Prescribing Information including Patient Information.
References: 1. PALSONIFY. Prescribing information 09/2025. Crinetics Pharmaceuticals, Inc; 2025. 2. Data on file. CRN00808-08 NDA 2.7.4 summary of clinical safety. Crinetics Pharmaceuticals, Inc; 2025. 3. Data on file. Clinical study report CRN00808-08. Crinetics Pharmaceuticals, Inc; 2025. 4. Data on file. Clinical study report CRN00808-09. Crinetics Pharmaceuticals, Inc; 2025.